These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 38337852)

  • 1. Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review.
    Zhang H; Houadj L; Wu KY; Tran SD
    Diagnostics (Basel); 2024 Feb; 14(3):. PubMed ID: 38337852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database.
    Anquetil C; Salem JE; Lebrun-Vignes B; Touhami S; Desbois AC; Maalouf G; Domont F; Allenbach Y; Cacoub P; Bodaghi B; Saadoun D
    J Autoimmun; 2020 Jul; 111():102454. PubMed ID: 32303423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
    Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
    Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-DRB1*04:05 is involved in the development of Vogt-Koyanagi-Harada disease-like immune-related adverse events in patients receiving immune checkpoint inhibitors.
    Takeuchi M; Meguro A; Nakamura J; Chikagawa R; Osada R; Shibuya E; Hasumi Y; Yamada N; Ishihara M; Mizuki N
    Sci Rep; 2023 Aug; 13(1):13580. PubMed ID: 37604934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis.
    Bomze D; Meirson T; Hasan Ali O; Goldman A; Flatz L; Habot-Wilner Z
    Ocul Immunol Inflamm; 2022 Jan; 30(1):191-197. PubMed ID: 32749899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Vogt-Koyanagi-Harada Disease-like Uveitis during Treatment by Anti-programmed Death Ligand-1 Antibody for Non-small Cell Lung Cancer: A Case Report.
    Suwa S; Tomita R; Kataoka K; Ueno S
    Ocul Immunol Inflamm; 2022 Aug; 30(6):1522-1526. PubMed ID: 33797309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VOGT-KOYANAGI-HARADA DISEASE-LIKE UVEITIS IN A PATIENT WITH ADVANCED MELANOMA TREATED BY SEQUENTIAL ADMINISTRATION OF NIVOLUMAB AND DABRAFENIB/TRAMETINIB THERAPY.
    Madoe A; Schauwvlieghe PP; Jacob J
    Retin Cases Brief Rep; 2023 Sep; 17(5):611-615. PubMed ID: 37643052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of uveitis events in real-world patients receiving immune checkpoint inhibitors based on the FAERS database.
    Fan Q; Chen H; Hu Y; Zhao B
    Cutan Ocul Toxicol; 2023 Jun; 42(2):68-73. PubMed ID: 37130046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uveitis associated with immune checkpoint inhibitors or BRAF/MEK inhibitors in patients with malignant melanoma.
    Sada I; Harada Y; Hiyama T; Mizukami M; Kan T; Kawai M; Kiuchi Y
    Melanoma Res; 2023 Dec; 33(6):539-546. PubMed ID: 37788106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Wang DY; Salem JE; Cohen JV; Chandra S; Menzer C; Ye F; Zhao S; Das S; Beckermann KE; Ha L; Rathmell WK; Ancell KK; Balko JM; Bowman C; Davis EJ; Chism DD; Horn L; Long GV; Carlino MS; Lebrun-Vignes B; Eroglu Z; Hassel JC; Menzies AM; Sosman JA; Sullivan RJ; Moslehi JJ; Johnson DB
    JAMA Oncol; 2018 Dec; 4(12):1721-1728. PubMed ID: 30242316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies.
    Sun JY; Qu Q; Lou YX; Hua Y; Sun GZ; Sun W; Kong XQ
    Int J Cardiol; 2021 Dec; 344():170-178. PubMed ID: 34563597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?
    Lee SM; Lee S; Cho HW; Min KJ; Hong JH; Song JY; Lee JK; Lee NW
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes.
    Dow ER; Yung M; Tsui E
    Ocul Immunol Inflamm; 2021 Jan; 29(1):203-211. PubMed ID: 32815757
    [No Abstract]   [Full Text] [Related]  

  • 17. Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer.
    Zhou L; Wei X
    Front Immunol; 2021; 12():701951. PubMed ID: 34504488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular and orbital side-effects of checkpoint inhibitors: a review article.
    Antoun J; Titah C; Cochereau I
    Curr Opin Oncol; 2016 Jul; 28(4):288-94. PubMed ID: 27136135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.
    Jessurun CAC; Vos JAM; Limpens J; Luiten RM
    Front Oncol; 2017; 7():233. PubMed ID: 29034210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
    Li Y; Liang X; Li H; Chen X
    Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.